DUBLIN, Sept. 21, 2015 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical company, today announced a nationwide partnership with the Caregiver Action Network (CAN), the nation's leading family caregiver organization, to provide thank you meals to 1,000 family caregivers across the country through a new initiative called Take 1 Moment.
Family caregiving is an enormous and growing issue in our country. Last year caregivers provided an estimated 17.9 billion hours of unpaid care, a contribution to the nation valued at $217.7 billion.
"On World Alzheimer's Day, we are extending our commitment to be there for families and loved ones living day-to-day with Alzheimer's through initiatives like Take 1 Moment," said Gavin Corcoran, MD, Chief Medical Officer. "We support the campaign's efforts to ease the burden on caregivers. We also remain committed to offering new therapeutic options for those with Alzheimer's disease, such as NAMZARIC."
Approximately 50 percent of people aged 85 and older have Alzheimer's disease. According to the Alzheimer's Association, by mid-century someone will develop Alzheimer's every 33 seconds and there will be nearly a million new cases per year.
The campaign asks people to #Take1Moment to share a memory or picture of someone they know or knew with Alzheimer's disease on Facebook, Twitter, Instagram or Pinterest. For the first 1,000 hashtags, the campaign will provide a thank you meal from Chef'd, a gourmet, fresh ingredient meal-kit delivery service, to a caregiver identified by CAN.
To learn more about #Take1Moment, visit the Caregiver Action Network website www.caregiveraction.org, which also has additional resources for Alzheimer's disease caregivers.
NAMZARIC is a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor. Namzaric was approved for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on certain doses of memantine hydrochloride and donepezil hydrochloride.
To learn more about a new treatment option that might be right for your loved one, visit Namzaric.com.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.allergan.com.
Allergan Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the risks associated with acquisition transactions; the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 (such periodic public filings having been filed under the "Actavis plc" name) and from time to time in Allergan's other investor communications . Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
SOURCE Allergan plc